IP Library Granted Patent US 11,246,886
Granted Patent B2
US 11,246,886 · App. 16/560,826 · Granted Feb 15, 2022

Treatment of autism and autism spectrum disorders with biotin compositions

Inventor: James R. Komorowski (Trumbull, CT)
Assignee: NUTRITION 21, LLC
A61K33/06G01N33/5008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,246,886
App. No.
16/560,826
Granted
Feb 15, 2022
Kind
B2
Abstract

The present application relates to the treatment of autism and autism spectrum disorders using biotin compositions.

Claims (14)

1. A method of treatment comprising assessing the biotin status of an individual with an autism spectrum disorder and subsequently providing magnesium biotinate in an amount between 10 mg/day to 1000 mg/day, to the individual to treat the autism spectrum disorder.

2. The method of claim 1 , wherein the assessing the biotin status of the individual with an autism spectrum disorder comprises obtaining samples from the individual and testing for markers associated with biotin deficiency.

3. The method of claim 2 , wherein the samples are obtained from blood, serum, peripheral blood mononuclear cell (PBMC), saliva, urine, feces or sweat from the individual with an autism spectrum disorder.

4. The method of claim 2 , wherein the samples are tested for markers indicative of impaired carboxylases.

5. The method of claim 4 , wherein the samples are tested for impaired propionyl-CoA carboxylase (PCC) or pyruvate carboxylase (PC).

6. The method of claim 5 , wherein the samples are tested for amino acids found at abnormal levels due to impaired PCC or PC or other carboxylase.

7. The method of claim 2 , wherein the samples are tested for biotin, propionic acid, pyruvate, or lactate.

8. The method of claim 2 , wherein the samples are tested for isoleucine, methionine, threonine, and valine.

9. The method of claim 2 , wherein the samples are tested for ratios of one amino acid over another.

10. The method of claim 2 , wherein the samples are tested for white blood cell count.

11. The method of claim 2 , wherein the samples are tested for mitochondrial function.

12. A method of treating an autism spectrum disorder comprising administering magnesium biotinate in an amount between 10 mg/day to 1000 mg/day, to an individual diagnosed with an autism spectrum disorder.

13. The method of claim 12 , wherein the type of autism spectrum disorder to be treated is related to low biotin levels, impaired carboxylase function, increased propionic acid levels, or increased levels of isoleucine, methionine, threonine, and/or valine.

14. The method of claim 12 , wherein the magnesium biotinate can be provided as a drug, supplement, medical food, food or biologic.

Assignments (3)
SECURITY INTEREST Recorded Nov 9, 2021
From: NUTRITION 21, LLC
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 058060/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2021
From: JDS THERAPEUTICS, LLC
To: NUTRITION 21, LLC
Reel/Frame 056933/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2019
From: KOMOROWSKI, JAMES R.
To: JDS THERAPEUTICS, LLC
Reel/Frame 050405/0106 →
Cited By (1)
US 12,257,238